HLS Therapeutics HLTRF Stock
HLS Therapeutics Price Chart
HLS Therapeutics HLTRF Financial and Trading Overview
| HLS Therapeutics stock price | 3 USD |
| Previous Close | 3.42 USD |
| Open | 4.71 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 4.71 - 4.77 USD |
| 52 Week Range | 3.2 - 10.96 USD |
| Volume | 2.5K USD |
| Avg. Volume | 5.58K USD |
| Market Cap | 209.99M USD |
| Beta (5Y Monthly) | 0.969215 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.62 USD |
| Forward Dividend & Yield | 0.15 (4.29%) |
| Ex-Dividend Date | April 27, 2023 |
| 1y Target Est | N/A |
HLTRF Valuation Measures
| Enterprise Value | 184.62M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.4051979 |
| Price/Book (mrq) | 1.2938776 |
| Enterprise Value/Revenue | 2.994 |
| Enterprise Value/EBITDA | 9.264 |
Trading Information
HLS Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.969215 |
| 52-Week Change | -56.61% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 10.96 USD |
| 52 Week Low | 3.2 USD |
| 50-Day Moving Average | 3.85 USD |
| 200-Day Moving Average | 6.03 USD |
HLTRF Share Statistics
| Avg. Volume (3 month) | 5.58K USD |
| Avg. Daily Volume (10-Days) | 10.41K USD |
| Shares Outstanding | 32.35M |
| Float | 14.52M |
| Short Ratio | N/A |
| % Held by Insiders | 6.16% |
| % Held by Institutions | 67.67% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.145 |
| Trailing Annual Dividend Yield | 4.23% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -41.79% |
| Operating Margin (ttm) | -22.37% |
| Gross Margin | 82.16% |
| EBITDA Margin | 32.31% |
Management Effectiveness
| Return on Assets (ttm) | -3.41% |
| Return on Equity (ttm) | -18.54% |
Income Statement
| Revenue (ttm) | 61.67M USD |
| Revenue Per Share (ttm) | 1.9 USD |
| Quarterly Revenue Growth (yoy) | 1.40% |
| Gross Profit (ttm) | 50.76M USD |
| EBITDA | 19.93M USD |
| Net Income Avi to Common (ttm) | -25774000 USD |
| Diluted EPS (ttm) | -0.8 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 21.21M USD |
| Total Cash Per Share (mrq) | 0.66 USD |
| Total Debt (mrq) | 95.2M USD |
| Total Debt/Equity (mrq) | 80.07 USD |
| Current Ratio (mrq) | 1.482 |
| Book Value Per Share (mrq) | 3.675 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 15.2M USD |
| Levered Free Cash Flow (ttm) | 14.27M USD |
Profile of HLS Therapeutics
| Country | United States |
| State | ON |
| City | Etobicoke |
| Address | 10 Carlson Court |
| ZIP | M9W 6L2 |
| Phone | 647-495-9000 |
| Website | https://www.hlstherapeutics.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 99 |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Q&A For HLS Therapeutics Stock
What is a current HLTRF stock price?
HLS Therapeutics HLTRF stock price today per share is 3 USD.
How to purchase HLS Therapeutics stock?
You can buy HLTRF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for HLS Therapeutics?
The stock symbol or ticker of HLS Therapeutics is HLTRF.
Which industry does the HLS Therapeutics company belong to?
The HLS Therapeutics industry is Drug Manufacturers-Specialty & Generic.
How many shares does HLS Therapeutics have in circulation?
The max supply of HLS Therapeutics shares is 31.8M.
What is HLS Therapeutics Price to Earnings Ratio (PE Ratio)?
HLS Therapeutics PE Ratio is now.
What was HLS Therapeutics earnings per share over the trailing 12 months (TTM)?
HLS Therapeutics EPS is -0.62 USD over the trailing 12 months.
Which sector does the HLS Therapeutics company belong to?
The HLS Therapeutics sector is Healthcare.